Medication repository program procedures modified, and money appropriated.
HF1103 modifies Minnesota’s medication repository program, which allows donated prescription drugs and medical supplies to be collected, inspected, and redistributed to eligible patients through central and local repositories. The bill updates the standards for accepting donations, including requirements that drugs and supplies be unopened, tamper-evident, properly stored, and generally have at least six months remaining before expiration, while preserving a limited exception for high-demand items that can still be used before expiration. It also clarifies donor documentation, inventory tracking, and inspection procedures, and continues to prohibit controlled substances and drop-box donations.
The bill also expands operational flexibility for repositories by allowing the central repository to purchase drugs from licensed wholesalers when donated inventory is insufficient, while requiring donated drugs to be used whenever possible. Local repositories that choose not to dispense suitable donated items must transfer them to the central repository along with donor documentation. Finally, the bill appropriates $900,000 per year in fiscal years 2026 and 2027 from the general fund to the Board of Pharmacy for a contract under the medication repository program, with the same amount built into the base for later years.
HF1103 would amend Minnesota Statutes section 151.555 governing the medication repository program, affecting the Board of Pharmacy, central and local repositories, donors, wholesalers, and patients who receive redistributed medications and supplies. The bill would formalize and tighten donation acceptance and recordkeeping rules, authorize wholesale purchasing to supplement donated inventory, and provide ongoing state funding to support program administration and operations.
Based on the bill text and available context, the measure appears generally supportive of expanding and stabilizing the medication repository program. The bill was authored by a bipartisan group of legislators and referred to the House Committee on Health Finance and Policy, suggesting broad policy interest in improving access to donated medications and supplies. No committee transcript or vote record is available here, so there is no evidence of recorded opposition or debate in the provided materials.
The main policy tension in HF1103 is between expanding access to donated medications and maintaining safety, accountability, and program integrity. The bill addresses this by keeping strict eligibility rules for donations, requiring pharmacist or practitioner inspection, and prohibiting controlled substances and drop-box collection. Another possible point of discussion is the new state appropriation and whether general-fund support for the Board of Pharmacy is the appropriate mechanism to sustain the program, though no specific objections are documented in the provided record.